Autor: |
Yao Hao Teo, Yao Neng Teo, Nicholas L. Syn, Cheryl Shumin Kow, Celine Shuen Yin Yoong, Benjamin Y. Q. Tan, Tiong‐Cheng Yeo, Chi‐Hang Lee, Weiqin Lin, Ching‐Hui Sia |
Jazyk: |
angličtina |
Rok vydání: |
2021 |
Předmět: |
|
Zdroj: |
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 10, Iss 5 (2021) |
Druh dokumentu: |
article |
ISSN: |
2047-9980 |
DOI: |
10.1161/JAHA.120.019463 |
Popis: |
Background Recent studies have increasingly shown that sodium‐glucose cotransporter 2 (SGLT2) inhibitors may have beneficial cardiovascular and metabolic effects in patients without diabetes mellitus. Hence, we conducted a systematic review and meta‐analysis to determine the effect of SGLT2 inhibitors on cardiovascular and metabolic outcomes in patients without diabetes mellitus. Methods and Results Four electronic databases (PubMed, Embase, Cochrane, and SCOPUS) were searched on August 30, 2020 for articles published from January 1, 2000 to August 30, 2020, for studies that examined the effect of SGLT2 inhibitors on cardiovascular and metabolic outcomes in patients without diabetes mellitus. A random‐effects pairwise meta‐analysis model was used to summarize the studies. A total of 8 randomized‐controlled trials were included with a combined cohort of 5233 patients. In patients without diabetes mellitus, those with heart failure treated with SGLT2 inhibitors had a 20% relative risk reduction in cardiovascular deaths and heart failure hospitalizations, compared with those who were not treated (risk ratio, 0.78; P |
Databáze: |
Directory of Open Access Journals |
Externí odkaz: |
|